{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:57Z","timestamp":1793090217465,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105573","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:20:03Z","timestamp":1788362403000},"page":"105573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Breast cancer treatment in patients with tuberculosis: Challenges and therapeutic considerations"],"prefix":"10.1016","volume":"227","author":[{"given":"Isabel Alejandra","family":"Escobar-Basurto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Chavez-Tahuilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Jimenez-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Llamas-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving Jesus","family":"Reyes-Barragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydee Cristina","family":"Verduzco-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-4067","authenticated-orcid":false,"given":"Bertha Alejandra","family":"Martinez-Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105573_bib1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s10549-011-1634-8","article-title":"Coexistence of breast cancer and tuberculosis in axillary lymph nodes: a case report and literature review","volume":"130","author":"Akbulut","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105573_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1148\/radiol.2243011236","article-title":"Drug-induced pneumonitis: thin-section CT findings in 60 patients","volume":"224","author":"Akira","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2026.105573_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105573_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105573_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/ctrv.2001.0228","article-title":"Drug interactions with the taxanes: clinical implications","volume":"27","author":"Baker","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105573_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200645030-00002","article-title":"Clinical pharmacokinetics of docetaxel","volume":"45","author":"Baker","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2026.105573_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib8","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S1473-3099(22)00227-4","article-title":"Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia","volume":"22","author":"Bergeron","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105573_bib9","unstructured":"Bethesda (M.D.): National Institute of Diabetes and Digestive and Kidney Diseases, 2012a. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Anastrozole."},{"key":"10.1016\/j.critrevonc.2026.105573_bib10","unstructured":"Bethesda (M.D.): National Institute of Diabetes and Digestive and Kidney Diseases, 2012b. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Letrozole."},{"key":"10.1016\/j.critrevonc.2026.105573_bib11","unstructured":"Bethesda (M.D.): National Institute of Diabetes and Digestive and Kidney Diseases, 2012c. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury - Exemestane."},{"key":"10.1016\/j.critrevonc.2026.105573_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-023-04550-7","article-title":"Pharmacology and pharmacokinetics of elacestrant","volume":"92","author":"Beumer","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/clpt.2011.372","article-title":"Effects of CYP induction by rifampicin on tamoxifen exposure","volume":"92","author":"Binkhorst","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105573_bib14","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/cts.13357","article-title":"Alternatives to rifampicin: a review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies","volume":"15","author":"Bolleddula","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.critrevonc.2026.105573_bib15","article-title":"Acid-fast positive and acid-fast negative mycobacterium tuberculosis: the koch paradox","volume":"5","author":"Catherine","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.critrevonc.2026.105573_bib16","first-page":"1946","article-title":"Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines","volume":"57","author":"Chang","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/cid\/ciw838","article-title":"Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105573_bib18","unstructured":"CHMP, n.d. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Kadcyla (Trastuzumab emtansina)."},{"key":"10.1016\/j.critrevonc.2026.105573_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/2141-9248.126619","article-title":"An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin","volume":"4","author":"Damodar","year":"2014","journal-title":"Ann. Med. Health Sci. Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105573_bib21","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.17511\/ijmrr.2016.i07.24","article-title":"Modified radical mastectomy for intraductal breast carcinoma in a patient with active pulmonary tuberculosis under thoracic epidural anaesthesia","volume":"4","author":"Devi","year":"2016","journal-title":"Int. J. Med. Res. Rev."},{"key":"10.1016\/j.critrevonc.2026.105573_bib22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jtcvs.2014.01.028","article-title":"Differentiating tuberculosis from sarcoidosis by sonographic characteristics of lymph nodes on endobronchial ultrasonography: a study of 165 patients","volume":"148","author":"Dhooria","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.critrevonc.2026.105573_bib23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.clinthera.2016.08.010","article-title":"Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase i open-label studies","volume":"38","author":"Dirix","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.critrevonc.2026.105573_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis","volume":"50","author":"Dobler","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.critrevonc.2026.105573_bib25","article-title":"Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis","volume":"15","author":"Dong","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105573_bib26","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2026.105573_bib27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1148\/rg.336125060","article-title":"Axillary staging of breast cancer: what the radiologist should know","volume":"33","author":"Ecanow","year":"2013","journal-title":"RadioGraphics"},{"key":"10.1016\/j.critrevonc.2026.105573_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bcp.14178","article-title":"Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours","volume":"86","author":"Elmeliegy","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.28982\/josam.1015461","article-title":"Evaluation of cancer patients receiving concurrent chemotherapy and antituberculosis treatment: review and case series of a single-center experience","volume":"6","author":"ERDUR","year":"2022","journal-title":"J. Surg. Med."},{"key":"10.1016\/j.critrevonc.2026.105573_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/03602532.2023.2215478","article-title":"Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms","volume":"55","author":"Ezhilarasan","year":"2023","journal-title":"Drug. Metab. Rev."},{"key":"10.1016\/j.critrevonc.2026.105573_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"Ferri","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105573_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1470-2045(25)00730-2","article-title":"Global, regional, and national burden of breast cancer among females, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"27","author":"GBD 2023 Breast Cancer Collaborators","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib33","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1199043","article-title":"Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors","volume":"13","author":"Gueiderikh","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib35","doi-asserted-by":"crossref","first-page":"8763","DOI":"10.3390\/curroncol30100632","article-title":"Dose volume and liver function test relationship following radiotherapy for right breast cancer: a multicenter study","volume":"30","author":"G\u00fczel\u00f6z","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib36","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001566","article-title":"JMM profile: rifampicin: a broad-spectrum antibiotic","volume":"71","author":"Hardie","year":"2022","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/dmd.113.054817","article-title":"Studies on the role of metabolic activation in tyrosine kinase inhibitor\u2013dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells","volume":"42","author":"Hardy","year":"2014","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2026.105573_bib38","article-title":"Precautions for patients taking aromatase inhibitors","volume":"11","author":"Heery","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1186\/s12885-018-4889-1","article-title":"Efficacy and safety of concurrent anti-cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study","volume":"18","author":"Hirashima","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105573_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-4515","article-title":"Abstract 4515: A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers","volume":"75","author":"Hoffman","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.17895","article-title":"Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer","volume":"28","author":"Hu","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105573_bib42","unstructured":"Humma, Z.E., Patel, P., 2026. Moxifloxacin."},{"key":"10.1016\/j.critrevonc.2026.105573_bib43","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1200\/JCO-25-01747","article-title":"Postmastectomy radiation therapy: an ASTRO-ASCO-SSO clinical practice guideline","volume":"43","author":"Jimenez","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib44","doi-asserted-by":"crossref","DOI":"10.25259\/IJMR_1673_2024","article-title":"Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: a systematic review & meta-analysis","volume":"161","author":"Kannabiran","year":"2025","journal-title":"Indian. J. Med. Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133064","article-title":"Adverse outcomes after non-chest surgeries in patients with pulmonary tuberculosis: a nationwide study","volume":"10","author":"Ke","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105573_bib46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0009-9236(98)90055-8","article-title":"Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin","volume":"64","author":"Kivist\u00f6","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105573_bib47","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1186\/s12879-019-4586-y","article-title":"Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006\u20132014","volume":"19","author":"Kmeid","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105573_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-CT153","article-title":"Abstract CT153: pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors","volume":"76","author":"Kulanthaivel","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00070-19","article-title":"The bewildering antitubercular action of pyrazinamide","volume":"84","author":"Lamont","year":"2020","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105573_bib50","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib51","article-title":"Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes","volume":"53","author":"Latham","year":"2025","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2026.105573_bib52","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.3390\/ijms23137383","article-title":"Low-dose rifabutin increases cytotoxicity in antimitotic-drug-treated resistant cancer cells by exhibiting strong P-gp-inhibitory activity","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105573_bib53","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib54","first-page":"29","article-title":"A review of the pharmacokinetic characteristics of immune checkpoint inhibitors and their clinical impact factors","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmgenomics. Pers. Med."},{"key":"10.1016\/j.critrevonc.2026.105573_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib56","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2\u2013positive cancer","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105573_bib57","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/cpt.1073","article-title":"Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: establishing induction relationships using ascending dose rifampin","volume":"104","author":"Lutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105573_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41433-023-02643-4","article-title":"Ethambutol and visual assessment in England: current practice and recommendations","volume":"38","author":"MacVinish","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.critrevonc.2026.105573_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2003.10.010","article-title":"Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells","volume":"483","author":"Magnarin","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib61","article-title":"ESTRO-ACROP guideline for positioning, immobilisation and setup verification for local and loco-regional photon breast cancer irradiation","volume":"28","author":"Mast","year":"2023","journal-title":"Tech. Innov. Patient Support. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib62","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","article-title":"European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer","volume":"23","author":"Meattini","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib63","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2026.0613","article-title":"American society of breast surgeons, society of breast imaging, and college of american pathology 2025 guidelines for the management of infectious and inflammatory lesions of the breast","author":"Mitchell","year":"2026","journal-title":"JAMA Surg."},{"key":"10.1016\/j.critrevonc.2026.105573_bib64","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official american thoracic society\/centers for disease control and prevention\/infectious diseases society of america clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105573_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-004-0799-9","article-title":"Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes","volume":"54","author":"Nallani","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib66","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00204-023-03531-2","article-title":"Comprehensive in vitro analysis evaluating the variable drug\u2013drug interaction risk of rifampicin compared to rifabutin","volume":"97","author":"Nilles","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ACO.0000000000001475","article-title":"Anesthetic considerations in cancer care","volume":"38","author":"Owolabi","year":"2025","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib68","series-title":"Advances in Clinical Chemistry","first-page":"33","article-title":"Chapter two - advances in TB testing","author":"Pagaduan","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105573_bib69","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/antibiotics3030317","article-title":"Drug resistance mechanisms in Mycobacterium tuberculosis","volume":"3","author":"Palomino","year":"2014","journal-title":"Antibiotics"},{"key":"10.1016\/j.critrevonc.2026.105573_bib70","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1060028018824088","article-title":"Neratinib in HER2-positive breast cancer patients","volume":"53","author":"Paranjpe","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105573_bib71","unstructured":"Rashmi Kumar, N., Schonfeld, R., Gradishar, W.J., Lurie, R.H., Moran, M.S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K.H., Anderson, B., Bailey, J., Burstein, H.J., Chen, N., Chew, H., Dang, C., Sloan Kettering Cancer Center, M., Elias, A.D., Giordano, S.H., Goetz, M.P., Jankowitz, R.C., Javid, S.H., Hutchinson Cancer Center Marilyn Leitch, F.A., Lyons, J., McCloskey, S., McShane, M., Patel, S.A., Rosenberger, L.H., Rugo, H.S., Santa-Maria, C.A., Hopkins Kimmel Cancer Center Bryan Schneider, J.P., Lou Smith, M., Advocacy Network Hatem Soliman, R., Speers, C., Telli, M.L., Wei, M., Wisinski, K.B., Yellala, A., Buffett Cancer Center Kay Yeung, P.T., Young, J.S., 2026. NCCN Guidelines Version 2.2026 Breast Cancer."},{"key":"10.1016\/j.critrevonc.2026.105573_bib72","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(25)00105-6","article-title":"Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis","volume":"13","author":"Ratnakumar","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.critrevonc.2026.105573_bib73","article-title":"Tuberculosis and pharmacological interactions: a narrative review","volume":"2","author":"Riccardi","year":"2020","journal-title":"Curr. Res. Pharmacol. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105573_bib74","unstructured":"Robert Baden, L., \u0424, C., Almyroudis, N.G., Baluch, A., Barros, N., Buss, B., \u0424 \u03a3, P., Cohen, S., Cooper, B., Dulanto Chiang, A., El Haddad, H., \u0424, \u00de, Gregg, K., Hakim, H., Ho, D., Husain, M., Khawaja, F., \u0424 \u00de, M.B.B.S., Logan, C., \u00de, \u0424, Manley, K., Multani, A., \u0424, M.B.B.S., Pande, A., \u0424, M.P.H., Pergam, S., \u0424 \u00de, M.P.H., Pisano, J., Saullo, J., \u0424 \u00de, P., Schuster, M., Seo, S.K., Shoham, S., Johns Hopkins, \u0424, Stenehjem, E., Taplitz, R., Topal, J., Wilson, J.W., Wong, E., Zimmer, A., Zeenat Diwan, N., Cassara, C.J., 2026. NCCN Guidelines Version 1.2026 Prevention and Treatment of Cancer-Related Infections."},{"key":"10.1016\/j.critrevonc.2026.105573_bib75","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","article-title":"Fulvestrant: pharmacokinetics and pharmacology","volume":"90","author":"Robertson","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105573_bib76","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105573_bib77","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","article-title":"Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?","volume":"15","author":"Rusu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105573_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110837","article-title":"Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: an ESTRO clinical practice guideline","volume":"207","author":"Ruysscher","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105573_bib79","first-page":"608","article-title":"Coexistence of breast cancer metastases and tuberculosis in axillary lymph nodes\u2014a rare association and review of the literature","volume":"41","author":"Salemis","year":"2010","journal-title":"Southeast. Asian J. Trop. Med. Public. Health"},{"key":"10.1016\/j.critrevonc.2026.105573_bib80","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cpt.1950","article-title":"Ribociclib drug-drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling","volume":"108","author":"Samant","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105573_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1441147","article-title":"Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement","volume":"15","author":"Sankar","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib82","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02516-18","article-title":"Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.critrevonc.2026.105573_bib83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.critrevonc.2026.105573_bib84","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent tuberculosis infection","volume":"385","author":"Shah","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105573_bib85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2125.2009.03370.x","article-title":"Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects","volume":"67","author":"Smith","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib87","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40268-016-0133-0","article-title":"Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms","volume":"16","author":"Srinivas","year":"2016","journal-title":"Drugs R. D."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105573_bib88","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105573_bib89","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2026.105573_bib90","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/1078-0432.CCR-21-1560","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with her2-expressing advanced solid tumors","volume":"27","author":"Takahashi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41523-025-00765-4","article-title":"Inflammatory breast cancer, best practice in the community setting","volume":"11","author":"Takahashi","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105573_bib92","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib93","first-page":"103","article-title":"Breast tuberculosis: diagnosis, clinical features & management","volume":"122","author":"Tewari","year":"2005","journal-title":"Indian. J. Med. Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib94","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40262-022-01144-z","article-title":"Evaluation of safety and clinically relevant drug\u2013drug interactions with tucatinib in healthy volunteers","volume":"61","author":"Topletz-Erickson","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2026.105573_bib95","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105573_bib96","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(24)02479-6","article-title":"Tuberculosis","volume":"405","author":"Trajman","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105573_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01043-21","article-title":"Model-based comparative analysis of rifampicin and rifabutin drug-drug interaction profile","volume":"65","author":"Tuloup","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.critrevonc.2026.105573_bib98","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.4103\/jcsr.jcsr_77_21","article-title":"Modified radical mastectomy under paravertebral block in a patient diagnosed with active pulmonary tuberculosis with moderate restriction of pulmonary function","volume":"11","author":"Uns","year":"2022","journal-title":"J. Clin. Sci. Res."},{"key":"10.1016\/j.critrevonc.2026.105573_bib99","unstructured":"U.S. Food and Drug Administration, 2017. NDA 208051 (NERLYNX\/neratinib): Multi-Discipline Review. Center for Drug Evaluation and Research."},{"key":"10.1016\/j.critrevonc.2026.105573_bib100","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","article-title":"Radiotherapy toxicities: mechanisms, management, and future directions","volume":"405","author":"Verginadis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105573_bib101","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/dmd.122.001131","article-title":"Activation\/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy","volume":"51","author":"Wang","year":"2023","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2026.105573_bib102","unstructured":"World Health Organization, 2024a. WHO consolidated guidelines on tuberculosis: module 3: diagnosis. World Health Organization."},{"key":"10.1016\/j.critrevonc.2026.105573_bib103","unstructured":"World Health Organization, 2024b. WHO consolidated guidelines on tuberculosis. Module 1, Prevention: tuberculosis preventive treatment. World Health Organization."},{"key":"10.1016\/j.critrevonc.2026.105573_bib104","unstructured":"World Health Organization, 2024c. WHO consolidated guidelines on tuberculosis. Module 4: treatment and care."},{"key":"10.1016\/j.critrevonc.2026.105573_bib105","unstructured":"World Health Organization, Global Programme on Tuberculosis and Lung Health (GTB), 2025. Global Tuberculosis Report 2025. World Health Organization."},{"key":"10.1016\/j.critrevonc.2026.105573_bib106","doi-asserted-by":"crossref","DOI":"10.20517\/2394-4722.2019.026","article-title":"Monoclonal antibody pharmacogenomics in cancer treatment","volume":"2019","author":"Yagishita","year":"2019","journal-title":"J. Cancer Metastas-.-. Treat."},{"key":"10.1016\/j.critrevonc.2026.105573_bib107","first-page":"79","article-title":"Bioavailability file: exemestane","volume":"32","author":"Yavuz","year":"2007","journal-title":"FABAD J. Pharm. Sci."},{"key":"10.1016\/j.critrevonc.2026.105573_bib108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00002018-200225020-00005","article-title":"Clinically significant interactions with drugs used in the treatment of tuberculosis","volume":"25","author":"Yew","year":"2002","journal-title":"Drug. Saf."},{"key":"10.1016\/j.critrevonc.2026.105573_bib109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.critrevonc.2026.105573_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12885-024-13350-y","article-title":"Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105573_bib111","article-title":"Coexisting lung cancer and pulmonary tuberculosis: a comprehensive review from incidence to management","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Rep. (Hoboken)"},{"key":"10.1016\/j.critrevonc.2026.105573_bib112","article-title":"Case report: management challenges of active tuberculosis complicated by thrombocytosis and squamous cell lung carcinoma","volume":"16","author":"Zhu","year":"2026","journal-title":"Front. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:59:56Z","timestamp":1793087996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":112,"alternative-id":["S1040842826004609"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105573","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer treatment in patients with tuberculosis: Challenges and therapeutic considerations","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105573"}}